Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

  • Snapshot
    • A 46-year-old woman presents to her gynecologist due to abnormal vaginal bleeding. She notices bleeding after intercourse and in between her menstrual cycles, which occurs every 28 days. This is the first time she has established care with a gynecologist. On pelvic examination, there is 2-cm exophytic mass originating in the cervix. Cervical biopsy demonstrates squamous cell carcinoma.
  • Introduction
    • Overview
      • cancer that typically arises from the transformation zone of the cervix
    • Preventive
      • HPV vaccine
        • indication
          • females and males ages 11-12 years (routinely given) up to the 26 years of age
        • not recommended during pregnancy
  • Epidemiology
    • Incidence
      • third most common cause of malignancy in women
        • first is endometrial and second is ovarian
      • average age of presentation is 45 years of age
    • Risk factors
      • human papillomavirus (HPV) infection
        • double-stranded DNA oncovirus
        • especially HPV-16 and HPV-18
      • multiple sexual partners
      • current smoking
      • immunosuppression
    • Pathophysiology
      • HPV infects the immature basal layer of the cervical epithelium in areas of epithelial breaks, leading to basal cell replication through the synthesis of oncogenic proteins
        • E6 and E7
          • believed to be responsible for HPV's oncogenic properties
          • E6 inhibits p53, a tumor suppressor protein
          • E7 inhibits retinoblastoma protein (Rb), a tumor suppressor protein
      • persistent HPV leads to squamous intraepithelial lesions
        • graded as
          • atypical squamous cells of undetermined significance (ASC-US)
            • abnormal cells that are not adequate enough to label as low-grade squamous intraepithelial lesion (LSIL)
          • low-grade squamous intraepithelial lesion (LSIL)
            • previously termed cervical intraepithelial neoplasia (CIN) 1
            • mild dysplasia
            • most cases regress spontaneously
              • a small number of cases progress to high-grade squamous intraepithelial lesions (HSIL)
          • atypical squamous cells, cannot rule out HSIL (ASC-H)
            • abnormal cells that likely consist of high-grade squamous intraepithelial lesions (HSIL)
          • high-grade squamous intraepithelial lesion (HSIL)
            • previously termed CIN 2 and CIN 3
            • moderate-to-severe dysplasia
            • carcinoma in situ
            • considered high risk for progressing to carcinoma
      • cervical carcinoma
        • squamous cell carcinoma is the most common (~80% of cases)
          • invades the underlying cervical stroma
        • adenocarcinoma is the second most common (~15% of cases)
    • Associated conditions
      • HIV
      • HPV
  • Presentation
    • Symptoms
      • asymptomatic in early stages
      • vaginal bleeding
        • can be post-coital, intermenstrual, postmenopausal, or spontaneous
      • bladder outlet obstruction in advanced lesions
        • pelvic pain
        • hematuria
        • renal failure
    • Physical exam
      • pelvic exam
        • superficial ulceration
        • exophytic tumor in some cases
        • indurated cervix may be found
  • Studies
    • Invasive studies
      • pap smear
        • cells from the transformation zone of the cervix are collected and placed on a slide
          • determines if the cells are normal, ASC-US, LSIL, ASC-H, HSIL, or cervical cancer
        • indications
          • women between the ages of 21-65 every 3 years or
          • women between the ages of 30-65 every 5 years with HPV testing
          • special circumstance
            • immunocompromised patients should be screened 1 year after the onset of sexual activity or by 21 years of age, which ever comes first
        • management
          • ASC-US
            • any age
              • repeat pap smear in 1 year
              • HPV DNA testing (preferred)
          • LSIL
            • 21-24 years of age
              • repeat pap smear in 1 year
            • ≥ 25 years of age
              • HPV DNA testing
          • ASC-H
            • any age
              • colposcopy with biopsy
          • HSIL
            • any age
              • colposcopy with biopsy
            • ≥ 25 years of age
              • immediate loop electrosurgical excision procedure (LEEP)
                • not if the patient is pregnant
          • cancer
            • imaging should be performed for clinical staging and risk assessment
      • colposcopy
        • allows for a magnified view of the cervix
          • helps identify precancerous and cancerous lesions with the use of acetic acid
        • indication
          • as a follow-up test in patients with abnormal pap smears, HPV testing, or gross abnormalities of the cervix, vagina, or vulva
            • can perform a directed cervical biopsy or excision via colposcopy
            • adequate colposcopy requires that the whole squamocolumnar junction and all lesions be completely visualized
      • cervical conization
        • indication
          • when cervical malignancy is suspected by cannot be determined with cervical biopsies
  • Differential
    • Cervicitis
      • differentiating factors
        • inflammation of the cervix, most commonly secondary to sexually transmitted infections (e.g., chlamydia and gonorrhea)
  • Treatment
    • Treatment is based on the staging, nodal status, and pathology
      • e.g., ≤ 4 cm tumor confined to the cervix is managed with surgical resection or radiation
1 of 0
Private Note

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options